AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for pre-mRNA splicing regulator USH1G

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q495M9

UPID:

USH1G_HUMAN

Alternative names:

Scaffold protein containing ankyrin repeats and SAM domain; Usher syndrome type-1G protein

Alternative UPACC:

Q495M9; Q8N251

Background:

The pre-mRNA splicing regulator USH1G, also known as Scaffold protein containing ankyrin repeats and SAM domain, plays a crucial role in pre-mRNA splicing. It regulates the release and transfer of U4/U6.U5 tri-snRNP complexes, contributing to the assembly of the pre-catalytic spliceosome on target pre-mRNAs. Additionally, it is involved in the recycling of snRNPs during splicing and plays a role in MAGI2-mediated endocytosis. It is also essential for the development and maintenance of cochlear hair cell bundles, required for normal hearing.

Therapeutic significance:

USH1G's involvement in Usher syndrome 1G, characterized by profound congenital sensorineural deafness, absent vestibular function, and progressive retinitis pigmentosa, highlights its therapeutic significance. Understanding the role of USH1G could open doors to potential therapeutic strategies for this condition.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.